Skip to main content
Lauren A Byers on Muck Rack

Lauren A Byers

As seen in: Markets Insider, Nature, Wiley Online Library, Yahoo Finance, Frontiers, The BMJ, EurekAlert!, Molecular Cancer, Medscape, Science Magazine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lauren A

Contact Lauren A, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

NOTCH1 acts as a tumor suppressor that induces early differentiation in head and neck cancer

|
By Lauren A Byers, JCI Insight, Chenfei Huang
| The Journal of Clinical Investigation
ResearchCell biologyOncology Open Access | 10.1172/jci.insight.202414 JCI Insight. https://doi.org/10.1172/jci.insight.202414. Copyright © 2026, Huang et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Open in Who Shared Issue with article?

Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer

|
By Melissa Johnson, Giulia Fabbri, Carmela Ciardullo, Judy Wang, Gerald S. Falchook, Suzanne Jones, Donald Strickland, Jacob Sands, Carl M Gay, Luis Tobalina, Sophie E. Willis, Jaime Rodriguez-Canales, Emma Jones, Alexander MacDonald, Caroline Kennedy, J. Pease, Jan Cosaert, Howard Burris III, Lauren A Byers, Robert J. Cardnell, Myria Nikolaou, Stein Schalkwijk, Liz Sainsbury, Philip Overend, Philip Szekeres
| Nature Verified
Abstract Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung cancer (SCLC). Here we report the dose-expansion results. Eligible patients received nanoparticle-formulated AZD2811 500 mg IV (Day 1; 21-day cycles) with granulocyte colony-stimulating factor (Day 8).
Open in Who Shared Issue with article?

From classical machine learning to emerging foundation models: review on multimodal data integration for cancer research

|
By Lauren A Byers
| Springer Professional
Title From classical machine learning to emerging foundation models: review on multimodal data integration for cancer research Authors Amgad Muneer Muhammad Waqas Maliazurina B. Saad Eman Showkatian Rukhmini Bandyopadhyay Hui Xu Wentao Li Joe Y. Chang Zhongxing Liao Cara Haymaker Luisa Solis Soto Carol C. Wu Natalie I. Vokes Xiuning Le Lauren A. Byers Don L. Gibbons John V.
Open in Who Shared Issue with article?
See all 365 licensed articles (372 Total)